Claims

5

15

- 1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising the steps of
 - i) contacting a test compound with a NPEPPS polypeptide,
 - ii) detect binding of said test compound to said NPEPPS polypeptide.
- 2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising the steps of
 - i) determining the activity of a NPEPPS polypeptide at a certain concentration of a test compound or in the absence of said test compound,
 - ii) determining the activity of said polypeptide at a different concentration of said test compound.
 - 3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising the steps of
 - i) determining the activity of a NPEPPS polypeptide at a certain concentration of a test compound,
- 25 ii) determining the activity of a NPEPPS polypeptide at the presence of a compound known to be a regulator of a NPEPPS polypeptide.
 - 4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.
 - 5. The method of any of claims 1 to 3, wherein the cell is in vitro.

WO 2005/075666 PCT/EP2005/000609 - 95 -

- 6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.
- 7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.
- 8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.
- 5 9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.
 - 10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.
 - 11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.
- 12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising the steps of
 - i) contacting a test compound with a NPEPPS polynucleotide,
- ii) detect binding of said test compound to said NPEPPS polynucleotide.
 - 13. The method of claim 12 wherein the nucleic acid molecule is RNA.
 - 14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.
 - 15. The method of claim 12 wherein the contacting step is in a cell-free system.
 - 16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.
- 20 17. The method of claim 12 wherein the test compound is coupled to a detectable label.

- 18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising the steps of
 - i) determining the amount of a NPEPPS polynucleotide in a sample taken from said mammal,

- ii) determining the amount of NPEPPS polynucleotide in healthy and/or diseased mammals.
- 19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising a therapeutic agent which binds to a NPEPPS polypeptide.
- 20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a NPEPPS polypeptide.
- 21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising a therapeutic agent which regulates the activity of a NPEPPS polypeptide, wherein said therapeutic agent is
- 20 i) a small molecule,

5

- ii) an RNA molecule,
- iii) an antisense oligonucleotide,
- iv) a polypeptide,
- v) an antibody, or
- vi) a ribozyme.

- 22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising a NPEPPS polynucleotide.
- 23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological

diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising a NPEPPS polypeptide.

- 24. Use of regulators of a NPEPPS for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal.
- 25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal comprising the steps of
 - i) identifying a regulator of NPEPPS,

20

- 15 ii) determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases in a mammal; and
 - iii) combining of said regulator with an acceptable pharmaceutical carrier.
 - 26. Use of a regulator of NPEPPS for the regulation of NPEPPS activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, muscle-skeleton diseases, neurological diseases, respiratory diseases, inflammation and urological diseases.